# PathAI

its Path-IO (Pathology-driven Immunotherapy Optimization) multimodal platform combines pathomics, radiomics and clinical data to predict immunotherapy response in non-small-cell lung cancer, and its PathAI Discovery platform supports PD-L1 and stromal TIL biomarker development for clinical trials.

Source: https://en.bioecon.ru/companies/pathai/
Updated: 2026-07-01

- Country: United States

## Technologies

- [AI pathology interpretation (computational pathology)](https://en.bioecon.ru/technology/ai-pathology-interpretation/)